# Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

> **NCT03206918** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 91 (actual)

## Conditions studied

- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Relapsed or Refractory Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT03206918
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2018-06-15
- **Final completion:** 2020-09-10
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206918, "Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03206918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*